07.20.23
Rank: #20 (Last year: #20)
¥820.21 Billion ($6.18 Billion)
Prior Fiscal: ¥703.3 Billion
Percentage Change: +16.6%
R&D Expenditure: ¥61.6B
Best FY22 Quarter: Q3 ¥214.6B
Latest Quarter: Q4 ¥202.2B
No. of Employees: 30,207
Global Headquarters: Shibuya City, Tokyo, Japan
KEY EXECUTIVES:
Toshiaki Takagi, Chairman of the Board
Shinjiro Saito, President and CEO
Hikaru Samejima, Group Senior Managing Executive Officer; President, Medical Care Solutions Company
Toshishiko Osada, Group Senior Managing Executive Officer; President, Cardiac and Vascular Company; Division President, Interventional Systems Division, Cardiac and Vascular Company
Antoinette Gawin, Group Managing Executive Officer; President, Blood and Cell Technologies Company; President and CEO, Terumo BCT Holding Corp.
Terumo began a technology integration with data management company Glooko in March 2022 to deliver new diabetes data sharing solutions together worldwide. The integration aims to help people with diabetes transfer recorded data from the MEDISAFE WITH insulin patch pump into the Glooko platform, so they can visualize insulin dosage, food, and activities in graphs more easily. The integration also intends to realize personalized remote patient monitoring and patient care more effectively.
As a next step, both companies will work on a way to transfer recorded data from MEDISAFE WITH to the Glooko mobile app directly via near-field communication (NFC). MEDISAFE WITH, at the time, was the world’s first insulin patch pump with direct NFC connection to the Glooko mobile app. The app uses patients’ personal smartphones to share diabetes data with their diabetes team anytime, anywhere.
“We believe this is a valuable solution for both patients and healthcare providers especially under the post COVID-19 ‘new normal’ lifestyle,” Hikaru Samejima, president of Terumo’s General Hospital Company, said in a company press release announcing the partnership.
MEDISAFE WITH notched a CE mark in November 2020 and Glooko’s solutions are currently used in 31 countries to digitally connect diabetes patients and their healthcare professional teams.
“…people with diabetes will be able to make more informed decisions with their data, and collaborate with their health care team,” Glooko CEO Russ Johannesson said in the same press release. “That data includes insulin, glucose, diet, activity and blood pressure. Having the best connectivity is imperative for delivering world-class care…”
The Japanese company posted FY22 revenue of ¥820.2 billion ($6.18 billion), increasing just over 7% from the previous fiscal year’s total. Japanese revenue was somewhat flat—with a slight 0.6% rise—mainly due to strong revenue from Pharmaceutical Solutions and new products in the vascular graft division. This was despite a delayed recovery in medical demand from the COVID-19 pandemic. Overseas revenue performed quite admirably with a sharp incline of 23.3% year on year—mainly due to recovery of overall medical demand, despite some localized impacts caused by COVID-19 in China.
Terumo’s Cardiac and Vascular business posted ¥480.6 billion in sales in FY22, ballooning 21% over the year prior. According to the company’s financial report, revenue increased in Japan amid growth in new product sales like drug-eluting coronary stents and thoracic stent grafts, offsetting weaker demand from the impact of the resurgence of COVID-19 cases. Vascular graft division performance was solid due to several new product launches in the U.S.
The Terumo MicroVention neurovascular business achieved the first U.S. clinical case of its next-gen FRED X flow diverter last February. FRED X features a proprietary nano-polymer surface modification to reduce clot formation on the device surface. Its self-expanding, braided nitinol mesh helps redirect blood flow and promote aneurysm occlusion. According to Terumo, FRED X has both the smallest and largest flow diversion systems available in the United States.
The FDA granted breakthrough device status to Terumo’s RelayBranch thoracic stent-graft system last March. RelayBranch is implanted in patients with thoracic aortic arch pathologies needing treatment that includes coverage of the innominate and left common carotid arteries. The system is comprised of a main body graft deployed in the ascending aorta, with two anterograde tunnels that give way to a large cannulation window. Branch grafts are then deployed in these tunnels for the innominate artery and left common carotid artery.
FDA approval for the Thoraflex Hybrid Frozen Elephant Trunk (FET) device for complex aortic arch disease came a month later. The single-use device combines a Gelweave polyester graft with a Nitinol self-expanding stent graft and is indicated for open surgical repair or replacement of damaged or diseased aortic arch and descending aorta vessels with or without involvement of the ascending aorta in cases of aneurysm and/or dissection. Thoraflex Hybrid has had CE mark approval since 2012, with over 13,000 devices sold commercially around the world over the past decade. The first U.S. commercial implant of the device happened in July.
Terumo Medical Care Solutions—formerly named General Hospital Company and changed last April—revenue expanded 3.5% to ¥191.7. In the company’s primary Japan market, new adhesion barrier products and prefillable syringes of the Hospital Care division grew, making up for impacts from the resurgence of COVID-19 cases. Further, Pharmaceutical Solutions sales trended strongly across the globe.
August saw approval from Japan’s Ministry of Health, Labour and Welfare for the G-Lasta Subcutaneous Injection 3.6 mg BodyPod, a drug-device combination product co-developed with Kyowa Kirin. The product is used on the day of chemotherapy to reduce febrile neutropenia, so patients can skip the required outpatient visit on the day after chemo. G-Lasta launched in Japan in December.
Blood and Cell Technologies (BCT) accrued proceeds of ¥147.6 billion, skyrocketing 22.4% over the prior fiscal year. Japanese revenue declined somewhat due to weaker demand for blood bags. Overseas revenue swelled substantially, driven by recovery in blood transfusion demand in Asia and other regions, as well as strong demand for blood component collection systems in North America.
The company’s Rika plasma donation system earned FDA clearance last March. The automated technology includes safety features to minimize operator errors, ensure there’s never more than 200 milliliters of blood outside the donor’s body at one time, and collects plasma in 35 minutes or less. An advanced control system monitors the process and provides alerts and visual cues to guide the operator. Rika makes automatic adjustments during each collection to enable a seamless operating experience and the ability to spend more time with the donor.
Terumo BCT rolled out the Quantum Flex Cell Expansion System, a bioreactor platform to support process development through commercial manufacturing for the cell and gene therapy sector, in September. The automated and functionally closed cell expansion system can progress autologous and allogeneic applications, along with viral vector and exosome production, across various bioreactor sizes for process efficiencies in batch size. Hollow-fiber perfusion tech offers a cell culture environment where cells gain continuous access to fresh media, waste removal, and gas exchange, ensuring optimal conditions for expansion. Advanced software supports cGMP compliance, with user authentication, batch records, and fleet management features.
¥820.21 Billion ($6.18 Billion)
Prior Fiscal: ¥703.3 Billion
Percentage Change: +16.6%
R&D Expenditure: ¥61.6B
Best FY22 Quarter: Q3 ¥214.6B
Latest Quarter: Q4 ¥202.2B
No. of Employees: 30,207
Global Headquarters: Shibuya City, Tokyo, Japan
KEY EXECUTIVES:
Toshiaki Takagi, Chairman of the Board
Shinjiro Saito, President and CEO
Hikaru Samejima, Group Senior Managing Executive Officer; President, Medical Care Solutions Company
Toshishiko Osada, Group Senior Managing Executive Officer; President, Cardiac and Vascular Company; Division President, Interventional Systems Division, Cardiac and Vascular Company
Antoinette Gawin, Group Managing Executive Officer; President, Blood and Cell Technologies Company; President and CEO, Terumo BCT Holding Corp.
Terumo began a technology integration with data management company Glooko in March 2022 to deliver new diabetes data sharing solutions together worldwide. The integration aims to help people with diabetes transfer recorded data from the MEDISAFE WITH insulin patch pump into the Glooko platform, so they can visualize insulin dosage, food, and activities in graphs more easily. The integration also intends to realize personalized remote patient monitoring and patient care more effectively.
As a next step, both companies will work on a way to transfer recorded data from MEDISAFE WITH to the Glooko mobile app directly via near-field communication (NFC). MEDISAFE WITH, at the time, was the world’s first insulin patch pump with direct NFC connection to the Glooko mobile app. The app uses patients’ personal smartphones to share diabetes data with their diabetes team anytime, anywhere.
“We believe this is a valuable solution for both patients and healthcare providers especially under the post COVID-19 ‘new normal’ lifestyle,” Hikaru Samejima, president of Terumo’s General Hospital Company, said in a company press release announcing the partnership.
MEDISAFE WITH notched a CE mark in November 2020 and Glooko’s solutions are currently used in 31 countries to digitally connect diabetes patients and their healthcare professional teams.
“…people with diabetes will be able to make more informed decisions with their data, and collaborate with their health care team,” Glooko CEO Russ Johannesson said in the same press release. “That data includes insulin, glucose, diet, activity and blood pressure. Having the best connectivity is imperative for delivering world-class care…”
The Japanese company posted FY22 revenue of ¥820.2 billion ($6.18 billion), increasing just over 7% from the previous fiscal year’s total. Japanese revenue was somewhat flat—with a slight 0.6% rise—mainly due to strong revenue from Pharmaceutical Solutions and new products in the vascular graft division. This was despite a delayed recovery in medical demand from the COVID-19 pandemic. Overseas revenue performed quite admirably with a sharp incline of 23.3% year on year—mainly due to recovery of overall medical demand, despite some localized impacts caused by COVID-19 in China.
Terumo’s Cardiac and Vascular business posted ¥480.6 billion in sales in FY22, ballooning 21% over the year prior. According to the company’s financial report, revenue increased in Japan amid growth in new product sales like drug-eluting coronary stents and thoracic stent grafts, offsetting weaker demand from the impact of the resurgence of COVID-19 cases. Vascular graft division performance was solid due to several new product launches in the U.S.
The Terumo MicroVention neurovascular business achieved the first U.S. clinical case of its next-gen FRED X flow diverter last February. FRED X features a proprietary nano-polymer surface modification to reduce clot formation on the device surface. Its self-expanding, braided nitinol mesh helps redirect blood flow and promote aneurysm occlusion. According to Terumo, FRED X has both the smallest and largest flow diversion systems available in the United States.
The FDA granted breakthrough device status to Terumo’s RelayBranch thoracic stent-graft system last March. RelayBranch is implanted in patients with thoracic aortic arch pathologies needing treatment that includes coverage of the innominate and left common carotid arteries. The system is comprised of a main body graft deployed in the ascending aorta, with two anterograde tunnels that give way to a large cannulation window. Branch grafts are then deployed in these tunnels for the innominate artery and left common carotid artery.
FDA approval for the Thoraflex Hybrid Frozen Elephant Trunk (FET) device for complex aortic arch disease came a month later. The single-use device combines a Gelweave polyester graft with a Nitinol self-expanding stent graft and is indicated for open surgical repair or replacement of damaged or diseased aortic arch and descending aorta vessels with or without involvement of the ascending aorta in cases of aneurysm and/or dissection. Thoraflex Hybrid has had CE mark approval since 2012, with over 13,000 devices sold commercially around the world over the past decade. The first U.S. commercial implant of the device happened in July.
Terumo Medical Care Solutions—formerly named General Hospital Company and changed last April—revenue expanded 3.5% to ¥191.7. In the company’s primary Japan market, new adhesion barrier products and prefillable syringes of the Hospital Care division grew, making up for impacts from the resurgence of COVID-19 cases. Further, Pharmaceutical Solutions sales trended strongly across the globe.
August saw approval from Japan’s Ministry of Health, Labour and Welfare for the G-Lasta Subcutaneous Injection 3.6 mg BodyPod, a drug-device combination product co-developed with Kyowa Kirin. The product is used on the day of chemotherapy to reduce febrile neutropenia, so patients can skip the required outpatient visit on the day after chemo. G-Lasta launched in Japan in December.
Blood and Cell Technologies (BCT) accrued proceeds of ¥147.6 billion, skyrocketing 22.4% over the prior fiscal year. Japanese revenue declined somewhat due to weaker demand for blood bags. Overseas revenue swelled substantially, driven by recovery in blood transfusion demand in Asia and other regions, as well as strong demand for blood component collection systems in North America.
The company’s Rika plasma donation system earned FDA clearance last March. The automated technology includes safety features to minimize operator errors, ensure there’s never more than 200 milliliters of blood outside the donor’s body at one time, and collects plasma in 35 minutes or less. An advanced control system monitors the process and provides alerts and visual cues to guide the operator. Rika makes automatic adjustments during each collection to enable a seamless operating experience and the ability to spend more time with the donor.
Terumo BCT rolled out the Quantum Flex Cell Expansion System, a bioreactor platform to support process development through commercial manufacturing for the cell and gene therapy sector, in September. The automated and functionally closed cell expansion system can progress autologous and allogeneic applications, along with viral vector and exosome production, across various bioreactor sizes for process efficiencies in batch size. Hollow-fiber perfusion tech offers a cell culture environment where cells gain continuous access to fresh media, waste removal, and gas exchange, ensuring optimal conditions for expansion. Advanced software supports cGMP compliance, with user authentication, batch records, and fleet management features.